TR200202077T2 - Prar nükleer reseptörleri için yeni ligandlar - Google Patents

Prar nükleer reseptörleri için yeni ligandlar

Info

Publication number
TR200202077T2
TR200202077T2 TR2002/02077T TR200202077T TR200202077T2 TR 200202077 T2 TR200202077 T2 TR 200202077T2 TR 2002/02077 T TR2002/02077 T TR 2002/02077T TR 200202077 T TR200202077 T TR 200202077T TR 200202077 T2 TR200202077 T2 TR 200202077T2
Authority
TR
Turkey
Prior art keywords
alkyl
ligands
prar
ascofuranone
nuclear receptors
Prior art date
Application number
TR2002/02077T
Other languages
English (en)
Inventor
Tamura Gakuzo
Ando Kunio
Magae Junji̇
Original Assignee
Nuclear Receptor Research Limited
Institute Of Research And Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclear Receptor Research Limited, Institute Of Research And Innovation filed Critical Nuclear Receptor Research Limited
Publication of TR200202077T2 publication Critical patent/TR200202077T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Orkil aldehid bölgesinin 2-pozisyonu ve/veya 4-pozisyonundaki hidroksil hidroksil grup(lar)ina ait hidrojen atom(lar)i; C1-15alkil, C1-15alkenil,, CH2COOH, CH2COO(C1-15)alkil, C(=O)(C1-15)alkil,C(=O)(CH2)1-15COOH,nikotinoil ya da izonikotinoil vb.ile yer degistiren(substitusyon)en az bir orkil aldehit bölgesine sahip askofuranon ve askofuranon homologlari ile homologlarindan olusan gruptan seçilen bilesikler olarak nükleer reseptör PPAR'lere (peroksisom proliferatörle aktiflestirilen reseptörler) ait ligandlar. Bu ligandlar; diyabetler; hipertansiyon veya serebrovasküler hastaliklar; arteryoskleroz; diyabet komplikasyonlari; kronik enflamasyon; kaseksi; sindirim sistemi kanserleri vb. tedavisi ve/veya önlenmesinden faydalidir.
TR2002/02077T 1999-03-11 2000-03-13 Prar nükleer reseptörleri için yeni ligandlar TR200202077T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10699699 1999-03-11

Publications (1)

Publication Number Publication Date
TR200202077T2 true TR200202077T2 (tr) 2002-11-21

Family

ID=14447842

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2002/02077T TR200202077T2 (tr) 1999-03-11 2000-03-13 Prar nükleer reseptörleri için yeni ligandlar
TR2001/03002T TR200103002T2 (tr) 1999-03-11 2000-03-13 PPAR nkleer resept”rleri i‡in yeni ligandlar

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/03002T TR200103002T2 (tr) 1999-03-11 2000-03-13 PPAR nkleer resept”rleri i‡in yeni ligandlar

Country Status (10)

Country Link
EP (1) EP1176134A4 (tr)
KR (1) KR20020010581A (tr)
CN (1) CN1348436A (tr)
AU (1) AU2943300A (tr)
BR (1) BR0009474A (tr)
CA (1) CA2366281A1 (tr)
MX (1) MXPA01009127A (tr)
NO (1) NO20014394L (tr)
TR (2) TR200202077T2 (tr)
WO (1) WO2000053563A1 (tr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2453913A1 (en) * 2001-08-06 2003-02-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for identifying substances which positively influence inflammatory conditions
EP1429756B1 (en) 2001-09-21 2006-11-22 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
JPWO2003063849A1 (ja) * 2002-01-31 2005-05-26 アリジェン株式会社 多重危険因子症候群の診断、予防又は治療用医薬組成物
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP4789618B2 (ja) * 2003-02-24 2011-10-12 株式会社Ｎｒｌファーマ 新規転写因子、その製法および用途
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2005126343A (ja) * 2003-10-22 2005-05-19 Inst Of Research & Innovation 免疫抑制用薬剤組成物
JP4545463B2 (ja) * 2004-02-16 2010-09-15 武 北原 新規転写因子の製造法及び用途
CN1956711B (zh) * 2004-05-20 2010-06-09 爱科来株式会社 过氧化物酶体增殖物激活受体（ppar）活化剂以及使用了该活化剂的药品、补充剂、功能性食品及食品添加剂
KR100986817B1 (ko) * 2008-06-03 2010-10-08 주식회사 이에스파워 태양광 장치의 방어방법 및 방어시스템
JP5546807B2 (ja) * 2009-07-01 2014-07-09 サントリーホールディングス株式会社 Ｐｐａｒリガンド剤
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2857010B1 (en) * 2012-05-29 2018-07-04 Institute of Mitochondria Science, Inc. Dihydroorotic acid dehydrogenase inhibitor
JP2018536011A (ja) * 2015-12-01 2018-12-06 テリアカ バイオメディカル インコーポレイテッドＴｈｅｒｉａｃ Ｂｉｏｍｅｄｉｃａｌｅ Ｉｎｃ． ＰＰＡＲγ活性化剤とその使用
EP3400209B1 (en) * 2016-01-05 2021-09-22 HOSHINO, Tatsuo Ascochlorin derivative and use thereof as ampk activator
EP3624849B1 (en) 2017-05-18 2025-12-24 Tatsuo Hoshino Combination of an ascochlorin derivative and an immune checkpoint inhibitor for treating cancer
WO2018216821A1 (en) * 2017-05-23 2018-11-29 Nrl Pharma, Inc. Use of ascochlorin derivative for combination therapy
JP7198805B2 (ja) * 2017-09-15 2023-01-04 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 神経疾患の予防及び治療に使用するためのメロテルペノイド化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3546073A (en) * 1968-08-13 1970-12-08 American Cyanamid Co Fusarium fermentation
US3995061A (en) * 1974-04-09 1976-11-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition and method of using the same
JPS5136450A (en) * 1974-09-20 1976-03-27 Chugai Pharmaceutical Co Ltd Asukofuranonjudotai no seiho
AU493677B2 (en) * 1975-02-28 1976-09-02 Okada Masashi Pharmaceutical composition for arteriosclerosis
GB1498334A (en) * 1976-03-19 1978-01-18 Okada M Ascofuranone derivative and process for preparing the sam
US4500544A (en) * 1981-09-10 1985-02-19 Chugai Seiyaku Kabushiki Kaisha Ascochlorin derivatives, and pharmaceutical composition containing the same
JPS62181271A (ja) * 1986-02-06 1987-08-08 Sagami Chem Res Center ３（２ｈ）−フラノン誘導体
WO1994004520A1 (fr) * 1992-08-11 1994-03-03 Immuno Japan Inc. Ascofuranone, et agent hypolipidemique, agent hypoglycemique et inhibiteur de glycation contenant chacun un derive d'ascofuranone en tant qu'ingredient actif
JPH0816057B2 (ja) * 1992-09-10 1996-02-21 田村 學造 グリケイション阻害剤
JPH07206838A (ja) * 1994-01-14 1995-08-08 Immuno Japan:Kk 新規なアスコフラノン誘導体並びにそれらを有効成分とする血中脂質低下剤、血糖低下剤、グリケイション阻害剤及び抗酸化剤
US5420334A (en) * 1994-04-04 1995-05-30 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
US5925657A (en) * 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8559598A (en) * 1997-08-08 1999-03-01 Ono Pharmaceutical Co. Ltd. Gamma-type regulators for peroxisome proliferator-activated receptor
AU1797700A (en) * 1998-12-14 2000-07-03 Nuclear Receptor Research Limited Novel ligands of nuclear receptor

Also Published As

Publication number Publication date
BR0009474A (pt) 2001-11-27
WO2000053563A1 (en) 2000-09-14
MXPA01009127A (es) 2003-07-14
AU2943300A (en) 2000-09-28
TR200103002T2 (tr) 2002-03-21
KR20020010581A (ko) 2002-02-04
CN1348436A (zh) 2002-05-08
NO20014394D0 (no) 2001-09-10
NO20014394L (no) 2001-11-12
CA2366281A1 (en) 2000-09-14
EP1176134A4 (en) 2004-06-30
EP1176134A1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
TR200103002T2 (tr) PPAR nkleer resept”rleri i‡in yeni ligandlar
Guan et al. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans
Ito et al. Positive correlation of plasma transforming growth factor-β1 levels with tumor vascularity in hepatocellular carcinoma
Teofoli et al. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars
Wetterberg The relationship between the pineal gland and the pituitary-adrenal axis in health, endocrine and psychiatric conditions
Holland Morphological features of dentine and pulp related to dentine sensitivity
JP2988902B2 (ja) ベンザルマロネートシランの製造方法
EP0907661A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING ALPHA-V-BETA5 MEDIATED ANGIOGENESIS.
Kerenyi et al. Why the incidence of cancer is increasing: the role of ‘light pollution’
DE60037818D1 (de) Ether-verbindungen, zusammensetzungen und ihre verwendung
ES2102678T3 (es) Composicion cosmetica filtrante fotoestable que contiene un filtro uv-a y un polimero filtro del tipo silicona-benzotriazol.
EA026578B1 (ru) Вещества, связывающие ядерные рецепторы
Walker et al. Sunscreens offer the same UVB protection factors for inflammation and immunosuppression in the mouse
Bar-Tana Peroxisome proliferator-activated receptor gamma (PPARγ) activation and its consequences in humans
Dong Anticancer activities of PPARγ in breast cancer are context-dependent
WO2001034094A9 (en) Novel compounds to treat diabetes and associated conditions
Furue et al. Dysregulated expression of transforming growth factor β and its type‐I and type‐II receptors in basal‐cell carcinoma
EP1419129A4 (en) USE OF BRANCHED FATTY ACIDS AND ITS DERIVATIVES FOR PAIN TREATMENT
Šeparović et al. Rapid hair depigmentation in patient treated with pazopanib
Lodillinsky et al. Bacillus Calmette-Guerin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells
McIntosh et al. TETRACYCLINE‐INDUCED TOOTH CHANGES, PART 4 DISCOLORATION AND HYPOPLASIA INDUCED BY TETRACYCLINE ANALOGUES
DE69229436D1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
JP2003534262A (ja) 紅斑形成および／または皮膚の炎症反応の予防および／または治療のためのアリールオキシム類の使用
Andreou et al. Effect of dietary restriction on induced hamster cheek pouch carcinogenesis
Galvin et al. Rectangular reticulate patches on the pretibial areas